Company Overview of Advaxis, Inc.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. Its lead product Axalimogene filolisbac (ADXS-HPV), an Lm-LLO immunotherapy product candidate, which completed its Phase II study used for the treatment of human papilloma virus (HPV) associated cancers, including cervical, head and neck, and anal cancer. The company is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen (PSA) antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candida...
305 College Road East
Princeton, NJ 08540
Founded in 2002
Key Executives for Advaxis, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $398.8K
Chief Operating Officer and Executive Vice President
Total Annual Compensation: $285.0K
Chief Scientific Officer and Executive Vice President
Total Annual Compensation: $331.2K
Compensation as of Fiscal Year 2014.
Advaxis, Inc. Key Developments
Advaxis Appoints Bradley Monk as Lead Cervical Cancer Advisor
Feb 1 16
Advaxis, Inc. announced the appointment of Bradley J. Monk, MD, FACOG, FACS as Lead Cervical Cancer Advisor to the Company. Dr. Monk will be leading the development of Advaxis Lm Technology platform and assisting with the Company's multiple clinical programs, including those in HPV-associated cancers (cervical, anal, and head and neck), HER2 expressing tumors and prostate cancer. Dr. Monk brings to Advaxis more than 25 years of experience in medical oncology and clinical research. Notably, he serves as the co-primary investigator of GOG 0265. Dr. Monk is currently director of the Division of Gynecologic Oncology at St. Joseph's Hospital and Medical Center.
Advaxis, Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-11-2016
Jan 8 16
Advaxis, Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-11-2016 . Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States.
FDA Lifts Advaxis, Inc.'s Clinical Hold
Dec 16 15
Advaxis, Inc. announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on all of the company’s Investigational New Drug (IND) applications for its three product candidates: axalimogene filolisbac (formerly ADXS-HPV), ADXS-PSA and ADXS-HER2. Advaxis will therefore resume all clinical trials with axalimogene filolisbac, ADXS-PSA and ADXS-HER2. In October of 2015, Advaxis received notification from the FDA that its IND applications for axalimogene filolisbac were put on clinical hold in response to the company’s submission of a safety report to the FDA. The clinical hold also included the INDs for ADXS-PSA and ADXS-HER2. Following discussions with the FDA and in accordance with their recommendations, the company agreed to implement certain risk mitigation measures, including revised study protocol inclusion /exclusion criteria, post-administration antibiotic treatment and patient surveillance and monitoring measures.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|